Bath & Body Works Declares Cash Dividend
- 34
COLUMBUS, Ohio, May 17, 2024 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE: BBWI) announced today the declaration of its regular quarterly dividend of $0.20 per share payable on June 21, 2024, to shareholders of record at the close of business on June 7, 2024.
ABOUT BATH & BODY WORKS:
Home of America’s Favorite Fragrances®, Bath & Body Works is a global leader in personal care and home fragrance, including top-selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. Powered by agility and innovation, the company’s predominantly U.S.-based supply chain enables the company to deliver quality, on-trend luxuries at affordable prices. Bath & Body Works serves and delights customers however and wherever they want to shop, from welcoming, in-store experiences at 1,850 company-operated Bath & Body Works locations in the U.S. and Canada and more than 480 international franchised locations to an online storefront at bathandbodyworks.com.
For further information, please contact:
Bath & Body Works, Inc.:
Investor Relations
Mike McGuire
[email protected]
Media Relations
Jamison Pack
[email protected]
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
- Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- Hyundai Motor America Reports May 2024 Sales
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of N-able, Inc. (NYSE: NABL) and Encourages Shareholders to Contact the Firm for Additional Information
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting